EPCAM and cancer: A clinical study (NCT00836654) was conducted in EpCAM+ cancer patients suffering from malignant ascites, demonstrating that catumaxomab treatment slowed deterioration in quality of life (QoL) for patients to achieve a prolonged survival period (138).